• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

手性醇和氨基酸的生物催化合成在药物开发中的应用。

Biocatalytic synthesis of chiral alcohols and amino acids for development of pharmaceuticals.

机构信息

SLRP Associates Consultation in Biotechnology, 572 Cabot Hill Road, Bridgewater, NJ 08807, USA.

出版信息

Biomolecules. 2013 Oct 2;3(4):741-77. doi: 10.3390/biom3040741.

DOI:10.3390/biom3040741
PMID:24970190
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4030968/
Abstract

Chirality is a key factor in the safety and efficacy of many drug products and thus the production of single enantiomers of drug intermediates and drugs has become increasingly important in the pharmaceutical industry. There has been an increasing awareness of the enormous potential of microorganisms and enzymes derived there from for the transformation of synthetic chemicals with high chemo-, regio- and enatioselectivities. In this article, biocatalytic processes are described for the synthesis of chiral alcohols and unntural aminoacids for pharmaceuticals.

摘要

手性是许多药物产品安全性和有效性的关键因素,因此,药物中间体和药物单一对映异构体的生产在制药行业变得越来越重要。人们越来越意识到微生物和酶的巨大潜力,可以高化学选择性、区域选择性和对映选择性转化合成化学品。本文描述了用于合成手性醇和药物中天然氨基酸的生物催化过程。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f13f/4030968/fc8de72e767d/biomolecules-03-00741-g031.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f13f/4030968/2bb8b97a7598/biomolecules-03-00741-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f13f/4030968/ddfb04f0676c/biomolecules-03-00741-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f13f/4030968/d4a85323ef64/biomolecules-03-00741-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f13f/4030968/8c1066858a9a/biomolecules-03-00741-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f13f/4030968/51be6d27df9b/biomolecules-03-00741-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f13f/4030968/7513acce108e/biomolecules-03-00741-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f13f/4030968/61828b088c0b/biomolecules-03-00741-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f13f/4030968/224c17deefc8/biomolecules-03-00741-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f13f/4030968/e05b2ea624d2/biomolecules-03-00741-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f13f/4030968/e7ee2b148e88/biomolecules-03-00741-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f13f/4030968/7f7e9790df45/biomolecules-03-00741-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f13f/4030968/8b566ad0b741/biomolecules-03-00741-g012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f13f/4030968/cd5847097b38/biomolecules-03-00741-g013.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f13f/4030968/96b4152296ba/biomolecules-03-00741-g014.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f13f/4030968/f0579a21d952/biomolecules-03-00741-g015.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f13f/4030968/f9bc1d73db35/biomolecules-03-00741-g016.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f13f/4030968/b5a0a13c49dc/biomolecules-03-00741-g017.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f13f/4030968/9842e07b75d3/biomolecules-03-00741-g018.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f13f/4030968/646915c812df/biomolecules-03-00741-g019.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f13f/4030968/c47b41672d0b/biomolecules-03-00741-g020.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f13f/4030968/a4f8bc4ed632/biomolecules-03-00741-g021.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f13f/4030968/ac54a9557e29/biomolecules-03-00741-g022.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f13f/4030968/26e493aa5c0d/biomolecules-03-00741-g023.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f13f/4030968/eb339452b783/biomolecules-03-00741-g024.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f13f/4030968/6a872962b04c/biomolecules-03-00741-g025.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f13f/4030968/36454e9ec71a/biomolecules-03-00741-g026.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f13f/4030968/82dac6db5d03/biomolecules-03-00741-g027.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f13f/4030968/f8b270b1a5a9/biomolecules-03-00741-g028.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f13f/4030968/3823be1d1173/biomolecules-03-00741-g029.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f13f/4030968/7aeb35be1167/biomolecules-03-00741-g030.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f13f/4030968/fc8de72e767d/biomolecules-03-00741-g031.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f13f/4030968/2bb8b97a7598/biomolecules-03-00741-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f13f/4030968/ddfb04f0676c/biomolecules-03-00741-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f13f/4030968/d4a85323ef64/biomolecules-03-00741-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f13f/4030968/8c1066858a9a/biomolecules-03-00741-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f13f/4030968/51be6d27df9b/biomolecules-03-00741-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f13f/4030968/7513acce108e/biomolecules-03-00741-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f13f/4030968/61828b088c0b/biomolecules-03-00741-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f13f/4030968/224c17deefc8/biomolecules-03-00741-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f13f/4030968/e05b2ea624d2/biomolecules-03-00741-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f13f/4030968/e7ee2b148e88/biomolecules-03-00741-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f13f/4030968/7f7e9790df45/biomolecules-03-00741-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f13f/4030968/8b566ad0b741/biomolecules-03-00741-g012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f13f/4030968/cd5847097b38/biomolecules-03-00741-g013.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f13f/4030968/96b4152296ba/biomolecules-03-00741-g014.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f13f/4030968/f0579a21d952/biomolecules-03-00741-g015.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f13f/4030968/f9bc1d73db35/biomolecules-03-00741-g016.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f13f/4030968/b5a0a13c49dc/biomolecules-03-00741-g017.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f13f/4030968/9842e07b75d3/biomolecules-03-00741-g018.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f13f/4030968/646915c812df/biomolecules-03-00741-g019.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f13f/4030968/c47b41672d0b/biomolecules-03-00741-g020.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f13f/4030968/a4f8bc4ed632/biomolecules-03-00741-g021.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f13f/4030968/ac54a9557e29/biomolecules-03-00741-g022.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f13f/4030968/26e493aa5c0d/biomolecules-03-00741-g023.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f13f/4030968/eb339452b783/biomolecules-03-00741-g024.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f13f/4030968/6a872962b04c/biomolecules-03-00741-g025.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f13f/4030968/36454e9ec71a/biomolecules-03-00741-g026.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f13f/4030968/82dac6db5d03/biomolecules-03-00741-g027.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f13f/4030968/f8b270b1a5a9/biomolecules-03-00741-g028.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f13f/4030968/3823be1d1173/biomolecules-03-00741-g029.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f13f/4030968/7aeb35be1167/biomolecules-03-00741-g030.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f13f/4030968/fc8de72e767d/biomolecules-03-00741-g031.jpg

相似文献

1
Biocatalytic synthesis of chiral alcohols and amino acids for development of pharmaceuticals.手性醇和氨基酸的生物催化合成在药物开发中的应用。
Biomolecules. 2013 Oct 2;3(4):741-77. doi: 10.3390/biom3040741.
2
Biocatalysis for synthesis of pharmaceuticals.生物催化在药物合成中的应用。
Bioorg Med Chem. 2018 Apr 1;26(7):1252-1274. doi: 10.1016/j.bmc.2017.05.023. Epub 2017 May 22.
3
Chemo-enzymatic synthesis of pharmaceutical intermediates.药物中间体的化学-酶合成。
Expert Opin Drug Discov. 2008 Feb;3(2):187-245. doi: 10.1517/17460441.3.2.187.
4
Biocatalysis: synthesis of chiral intermediates for drugs.生物催化:药物手性中间体的合成
Curr Opin Drug Discov Devel. 2006 Nov;9(6):741-64.
5
Microbial/enzymatic synthesis of chiral pharmaceutical intermediates.手性药物中间体的微生物/酶促合成
Curr Opin Drug Discov Devel. 2003 Nov;6(6):902-20.
6
Biocatalytic synthesis of intermediates for the synthesis of chiral drug substances.用于合成手性药物中间体的生物催化合成。
Curr Opin Biotechnol. 2001 Dec;12(6):587-604. doi: 10.1016/s0958-1669(01)00266-x.
7
Enzymatic synthesis of chiral intermediates for pharmaceuticals.用于药物的手性中间体的酶促合成。
J Ind Microbiol Biotechnol. 2003 May;30(5):252-9. doi: 10.1007/s10295-003-0032-6. Epub 2003 Mar 25.
8
Synthesizing Chiral Drug Intermediates by Biocatalysis.生物催化合成手性药物中间体。
Appl Biochem Biotechnol. 2020 Sep;192(1):146-179. doi: 10.1007/s12010-020-03272-3. Epub 2020 Apr 22.
9
Biocatalytic ketone reduction--a powerful tool for the production of chiral alcohols--part I: processes with isolated enzymes.生物催化酮还原——生产手性醇的强大工具——第一部分:使用分离酶的过程。
Appl Microbiol Biotechnol. 2007 Aug;76(2):237-48. doi: 10.1007/s00253-007-1002-0. Epub 2007 May 22.
10
Nanophotonic Platforms for Chiral Sensing and Separation.用于手性传感和分离的纳米光子学平台。
Acc Chem Res. 2020 Mar 17;53(3):588-598. doi: 10.1021/acs.accounts.9b00460. Epub 2020 Jan 8.

引用本文的文献

1
Enzymatic synthesis of four stereoisomers of 3-substituted-4-hydroxypiperidines by carbonyl reductase-catalyzed reduction.通过羰基还原酶催化还原酶法合成3-取代-4-羟基哌啶的四种立体异构体
RSC Adv. 2025 Jun 26;15(26):21133-21141. doi: 10.1039/d5ra02485d. eCollection 2025 Jun 16.
2
Highly efficient synthesis of the chiral ACE inhibitor intermediate (R)-2-hydroxy-4-phenylbutyrate ethyl ester via engineered bi-enzyme coupled systems.通过工程化双酶偶联系统高效合成手性血管紧张素转换酶抑制剂中间体(R)-2-羟基-4-苯基丁酸乙酯
Bioresour Bioprocess. 2024 Oct 15;11(1):99. doi: 10.1186/s40643-024-00814-z.
3
Effective engineering of a ketoreductase for the biocatalytic synthesis of an ipatasertib precursor.

本文引用的文献

1
Biocatalysis in organic chemistry and biotechnology: past, present, and future.生物催化在有机化学和生物技术中的过去、现在和未来。
J Am Chem Soc. 2013 Aug 28;135(34):12480-96. doi: 10.1021/ja405051f. Epub 2013 Aug 20.
2
Sustainable practices in medicinal chemistry: current state and future directions.药用化学中的可持续实践:现状和未来方向。
J Med Chem. 2013 Aug 8;56(15):6007-21. doi: 10.1021/jm400250p. Epub 2013 May 9.
3
Chemo-enzymatic synthesis of pharmaceutical intermediates.药物中间体的化学-酶合成。
用于生物催化合成阿哌沙班前体的酮还原酶的有效工程改造。
Commun Chem. 2024 Feb 28;7(1):46. doi: 10.1038/s42004-024-01130-5.
4
A short-chain carbonyl reductase mutant is an efficient catalyst in the production of (R)-1,3-butanediol.一种短链羰基还原酶突变体是(R)-1,3-丁二醇生产中的高效催化剂。
Microb Biotechnol. 2023 Jun;16(6):1333-1343. doi: 10.1111/1751-7915.14249. Epub 2023 Mar 22.
5
Enantioseparation in Hierarchically Porous Assemblies of Homochiral Cages.同手性笼状结构分级多孔聚集体中的对映体拆分
ACS Cent Sci. 2022 May 25;8(5):562-570. doi: 10.1021/acscentsci.1c01571. Epub 2022 Apr 22.
6
Deracemization of 1-phenylethanols in a one-pot process combining Mn-driven oxidation with enzymatic reduction utilizing a compartmentalization technique.利用分隔技术,通过锰驱动氧化与酶促还原相结合的一锅法实现1-苯乙醇的消旋化。
RSC Adv. 2022 Apr 6;12(17):10619-10624. doi: 10.1039/d2ra01326f. eCollection 2022 Mar 31.
7
Versatile selective evolutionary pressure using synthetic defect in universal metabolism.通用代谢中的合成缺陷实现多功能选择性进化压力
Nat Commun. 2021 Nov 25;12(1):6859. doi: 10.1038/s41467-021-27266-9.
8
Self-sufficient asymmetric reduction of β-ketoesters catalysed by a novel and robust thermophilic alcohol dehydrogenase co-immobilised with NADH.由一种新型且稳定的嗜热醇脱氢酶与NADH共固定化催化的β-酮酯的自足不对称还原反应。
Catal Sci Technol. 2021 Mar 12;11(9):3217-3230. doi: 10.1039/d1cy00268f.
9
Overview on Multienzymatic Cascades for the Production of Non-canonical α-Amino Acids.用于生产非天然α-氨基酸的多酶级联反应概述
Front Bioeng Biotechnol. 2020 Aug 11;8:887. doi: 10.3389/fbioe.2020.00887. eCollection 2020.
10
Highly enantioselective synthesis of (R)-1,3-butanediol via deracemization of the corresponding racemate by a whole-cell stereoinverting cascade system.通过全细胞立体反转级联系统对相应外消旋体进行外消旋化,高对映选择性合成(R)-1,3-丁二醇。
Microb Cell Fact. 2020 Jun 8;19(1):125. doi: 10.1186/s12934-020-01384-3.
Expert Opin Drug Discov. 2008 Feb;3(2):187-245. doi: 10.1517/17460441.3.2.187.
4
On the development of new biocatalytic processes for practical pharmaceutical synthesis.关于实用药物合成中新生物催化工艺的开发。
Curr Opin Chem Biol. 2013 Apr;17(2):284-92. doi: 10.1016/j.cbpa.2013.01.017. Epub 2013 Feb 22.
5
The synthesis and SAR of calcitonin gene-related peptide (CGRP) receptor antagonists derived from tyrosine surrogates. Part 1.来源于替代酪氨酸的降钙素基因相关肽(CGRP)受体拮抗剂的合成和构效关系研究。第 1 部分。
Bioorg Med Chem Lett. 2012 Jul 15;22(14):4723-7. doi: 10.1016/j.bmcl.2012.05.074. Epub 2012 Jun 1.
6
Engineering the third wave of biocatalysis.工程化第三波生物催化。
Nature. 2012 May 9;485(7397):185-94. doi: 10.1038/nature11117.
7
Directed evolution drives the next generation of biocatalysts.定向进化推动了下一代生物催化剂的发展。
Nat Chem Biol. 2009 Aug;5(8):567-73. doi: 10.1038/nchembio.203.
8
8-(4-Methoxyphenyl)pyrazolo[1,5-a]-1,3,5-triazines: selective and centrally active corticotropin-releasing factor receptor-1 (CRF1) antagonists.8-(4-甲氧基苯基)吡唑并[1,5-a]-1,3,5-三嗪:选择性中枢活性促肾上腺皮质激素释放因子受体-1(CRF1)拮抗剂。
J Med Chem. 2009 May 14;52(9):3073-83. doi: 10.1021/jm9000242.
9
Biocatalysis in development of green pharmaceutical processes.绿色制药工艺开发中的生物催化
Curr Opin Chem Biol. 2009 Feb;13(1):43-50. doi: 10.1016/j.cbpa.2009.01.018. Epub 2009 Mar 4.
10
High-affinity CRF1 receptor antagonist NBI-34041: preclinical and clinical data suggest safety and efficacy in attenuating elevated stress response.高亲和力促肾上腺皮质激素释放因子1受体拮抗剂NBI-34041:临床前和临床数据表明其在减轻应激反应升高方面具有安全性和有效性。
Neuropsychopharmacology. 2007 Sep;32(9):1941-9. doi: 10.1038/sj.npp.1301328. Epub 2007 Feb 7.